Changes in the gut mycobiome in pediatric patients in relation to the clinical activity of Crohn's disease

Table 1 Clinical data from patients with Crohn’s disease and healthy subjects

	Group Ia (n = 50)	Group Ib (n = 16)	Group II (n = 39)	Control (n = 40)
General characteristics
Male:Female (ratio)	29:21 (1.38)	8:8 (1)	22:17 (1.29)	15:25 (0.6)
Age (years), mean ± SD	13 ± 2.9	15 ± 2.8	12.5 ± 4.3	11 ± 4.1
BMI (kg/m2), mean ± SD	17.0 ± 3.1	18.1 ± 2.7	18.1 ± 3.2	18.3 ± 3.8
PCDAI, mean ± SD	34.4 ± 12.7	38.2 ± 18.6	4.1 ± 3.9	N/A
Disease distribution by Paris classification (number of patients)
A1a	4	2	7
A1b	46	14	30
A2	0	2	2
L1	2	1	2
L2	6	2	7
L3	16	4	12
L4aL1	8	2	6
L4aL2	8	3	5
L4aL3	10	4	7
B1	39	11	27
B2	11	5	12

Group Ia: Active/newly diagnosed Crohn's disease (CD); Group Ib: Active/previously diagnosed and treated CD; Group II: Non-active CD; control: Healthy subjects; Paris classification: Age: A1a (0–10 yr), A1b (10–17 yr), A2 (17–40 yr); Location: L1 (distal 1/3 ileum and/or limited cecal disease), L2 (colonic), L3 (ileocolonic), L4a (upper disease proximal to ligament of Treitz), L4b (upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum); Behaviour: B1 (non-structuring non-penetrating), B2 (structuring), B3 (penetrating), B2B3 (both penetrating and structuring disease either at the same or different times); BMI: Body mass index; PCDAI: Pediatric Crohn’s disease activity index; N/A: Not applicable.